Table 1.

Patient's serum biochemistry evolution and treatment protocol.

	Calcium	Phosphate	PTH*	ALP	25(OH)D2	1,25(OH)2D3	U Ca/cr (urine sample)	TmP/GFR
Range	2.2–2.54 mmol/L	1.41–2.17 mmol/L	15–65 ng/mL	151–342 U/L	> 30 ng/mL	20–80 pg/mL	<0.7 mmol/mmol	1.04–2.79mmol/L
Baseline	1.7	1.1	427	2,380	13	528	0	1.06
FIRST PHASE TREATMENT
5,000 U vitamin D3 3,000 mg Ca/kg/d 1 month
Start	1.7	1.1	427	2,380	13		0	1.06
End	1.69	1.09	574	2,132	37		0.19	1.43
SECOND PHASE TREATMENT
iv calcium 45 mg/kg/d 4 months
Start	2.23	0.63	427	1,653			0.78	1.43
End	2.18	0.98	350	1,569			0.94	1.47
THIRD PHASE TREATMENT
Cinacalcet 0.27 mg/kg/d 2 months
Start	2.18	0.98	350		62		2.57	1.47
End	2.4	1.91	94					2.85
6 months of follow-up	2.33	1.51	23	304				2.15

PTH, parathyroid hormone,

^*measured by an electrochemiluminescence assay that detects full-length PTH (1–84). ALP, alkaline phosphatase. 25 (OH)D₂, 25-hydroxyvitamin D; 1,25(OH)₂D₃, 1,25-dihydroxyvitamin D3; U Ca/cr, urinary calcium/creatinine ratio; TmP/GFR, tubular maximum reabsorption of phosphate per unit of glomerular filtrate; iv, intravenous.